-
Signature
-
/s/ Michael A. Metzger, Attorney-in-Fact
-
Issuer symbol
-
SNDX
-
Transactions as of
-
14 Aug 2025
-
Net transactions value
-
-$460,380
-
Form type
-
4
-
Filing time
-
18 Aug 2025, 17:02:20 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Podlesak Dennis |
Director |
C/O SYNDAX PHARMACEUTICALS, INC., 730 THIRD AVENUE, FLOOR 9, NEW YORK |
/s/ Michael A. Metzger, Attorney-in-Fact |
18 Aug 2025 |
0001314595 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
SNDX |
Common Stock |
Options Exercise |
$138,240 |
+19,200 |
+10% |
$7.20 |
210,963 |
14 Aug 2025 |
Direct |
|
| transaction |
SNDX |
Common Stock |
Sale |
$272,521 |
-19,200 |
-9.1% |
$14.19 |
191,763 |
14 Aug 2025 |
Direct |
F1, F2 |
| transaction |
SNDX |
Common Stock |
Options Exercise |
$138,240 |
+19,200 |
+10% |
$7.20 |
210,963 |
15 Aug 2025 |
Direct |
|
| transaction |
SNDX |
Common Stock |
Sale |
$298,408 |
-19,200 |
-9.1% |
$15.54 |
191,763 |
15 Aug 2025 |
Direct |
F1, F3 |
| transaction |
SNDX |
Common Stock |
Options Exercise |
$138,240 |
+19,200 |
+10% |
$7.20 |
210,963 |
18 Aug 2025 |
Direct |
|
| transaction |
SNDX |
Common Stock |
Sale |
$304,170 |
-19,200 |
-9.1% |
$15.84 |
191,763 |
18 Aug 2025 |
Direct |
F1, F4 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
SNDX |
Stock Options (Right to buy) |
Options Exercise |
$0 |
-19,200 |
-100% |
$0.000000 |
0 |
14 Aug 2025 |
Common Stock |
19,200 |
$7.20 |
Direct |
F5 |
| transaction |
SNDX |
Stock Options (Right to buy) |
Options Exercise |
$0 |
-14,400 |
-100% |
$0.000000 |
0 |
15 Aug 2025 |
Common Stock |
14,400 |
$7.20 |
Direct |
F5 |
| transaction |
SNDX |
Stock Options (Right to buy) |
Options Exercise |
$0 |
-4,800 |
-100% |
$0.000000 |
0 |
15 Aug 2025 |
Common Stock |
4,800 |
$7.20 |
Direct |
F5 |
| transaction |
SNDX |
Stock Options (Right to buy) |
Options Exercise |
$0 |
-19,200 |
-100% |
$0.000000 |
0 |
18 Aug 2025 |
Common Stock |
19,200 |
$7.20 |
Direct |
F5 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: